Systemic Lupus Erythematosus

Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.

An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.

Pooled data from the phase 3 TULIP program offer additional insight into the effects of anifrolumab use in people with moderate-to-severe systemic lupus erythematosus.

Compared with those without SLE, those with SLE had a higher risk of fetal morbidity and mothers were almost 4 times as likely to require a blood transfusion or develop a cerebrovascular disorder.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.

The 2-phase study analyzed the association of plasma vitamin D levels with clinical phenotype, serology, and disease variables in a large cohort of patients with systemic lupus erythematosus living in India.

Anxiety and depression can limit engagement with healthcare or treatment leading to later diagnosis, poor treatment adherence, and poor disease control with associated negative sequelae.

Hydroxychloroquine dosing higher than 6 mg/kg was associated with a 15-year risk of nearly 22%, while retinopathy risk with shorter duration of use was significantly lower.

Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.

Dall'Era notes that it is important for rheumatologists to understand that the current endpoints for SLE clinical trials, such as SRI-4 and BICLA, are complex and imperfect. 

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

A significantly larger portion of patients in the telitacicept 160 mg achieved SR14 response compared to the placebo group.

"Infections are one of the key determinants of early morbidity and mortality of patients with SLE, strongly linked to disease activity and immunosuppression."

Preventing chronic damage accrual is one of the top treatment targets, as it is linked to increased mortality and decreased quality of life.

A statistically significant elevated risk of SLE was shown among women with low sleep, depression, and bodily pain when compared with those without these concomitant issues.

"Surveys of patients with SLE and other autoimmune and inflammatory rheumatic diseases have identified vaccine hesitancy in up to 50% of patients, which may be related to concerns about side effects, potential disease flares, or lack of data among patients with SLE.”

Findings demonstrate the utility of machine learning in aiding clinical risk stratification within a complex patient cohort.

The findings of this study of anti-CD19 directed CAR T cell therapy offers new hope for the most severe and refractory cases.

Fatigue, a highly multifactorial manifestation of lupus, can be related to disease activity or independent of the disease itself. Investigators determined whether fatigue could be a significant confounder of Physician Global Assessment ratings.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2022.

The effect of sleep health on disease prevention may have a profound impact on women when it comes to systemic lupus erythematosus (SLE).

In SLE, higher doses of prednisolone and the use of immunosuppressive agents, such as cyclophosphamide, have been associated with higher rates of infective sequelae.

The Lupus Research Alliance's 2022 Global Team Science Awards (GTSA) grant will provide $3 million for 3 years to each of the winners.

"The high prevalence of severe infection in newly diagnosed SLE implies that infections may be related to the underlying immune disturbance of SLE itself.”